Prime-boost with Chikungunya virus E2 envelope protein combined with Poly (I:C) induces specific humoral and cellular immune responses

Amaral, Marcelo Pires; Coirada, Fernanda Caroline; Apostólico, Juliana de Souza; Tomita, Nádia; Fernandes, Edgar Ruz; Souza, Higo Fernando Santos; Chura-Chambi, Rosa Maria; Morganti, Lígia; Boscardin, Sílvia Beatriz; Rosa, Daniela Santoro

doi:10.1016/j.crimmu.2021.03.001

Cited by 7 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the induction of robust cellular immune responses is a desirable vaccine ability, and mapping the specific sequences recognized by T CD4 + /CD8 + T cells is a powerful tool to design vaccines. Here, DNA immunization in both homologous and heterologous regimens generated a large number of IFN-γ-secreting cells, as previously observed with a DNA vaccine encoding E2 [ 36 , 74 ] or E1 + E2 + E3 [ 37 ]. Mapping of the immunogenic epitopes revealed that high numbers of IFN-γ-secreting cells were directed to E2 1–20 and E2 21–40 , which were also described after immunization of BALB/c mice with a peptide vaccine plus CpG ODN [ 75 ], and after CHIKV infection in mice [ 76 ].…”

Section: Discussionmentioning

confidence: 62%

“…E2* recombinant protein was produced in BL21 (DE3) bacteria after transformation with the pET21a-E2* plasmid as previously described [ 74 ]. Briefly, bacteria were inoculated in 1 L of Luria-Bertani (LB) medium containing ampicillin (100 μg/mL) (Sigma-Aldrich, San Luis, USA), and were grown at 37 °C, 250 rpm to an optical density (OD) of 600 nm between 0.6 and 0.8, respectively.…”

Section: Methodsmentioning

confidence: 99%

“…To evaluate E2*-specific antibody titers [ 74 ], high-binding ELISA plates (Costar®, Corning, NY, USA)) were coated with 5 μg/mL of the recombinant protein diluted in PBS overnight at room temperature. Plates were washed with 0.02% PBST after each step, and the wells were blocked with PBST, BSA (1% v / v ), and nonfat milk (5% v / v ) for 2 h. Sera from immunized mice were serially diluted in 100 μL of block solution and incubated for 2 h. After that, plates were incubated for 2 h with goat horseradish peroxidase-labeled anti-mouse IgG (1:10,000, KPL).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity

Coirada

Fernandes

Mello

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) has become a significant public health concern due to the increasing number of outbreaks worldwide and the associated comorbidities. Despite substantial efforts, there is no specific treatment or licensed vaccine against CHIKV to date. The E2 glycoprotein of CHIKV is a promising vaccine candidate as it is a major target of neutralizing antibodies during infection. In this study, we evaluated the immunogenicity of two DNA vaccines (a non-targeted and a dendritic cell-targeted vaccine) encoding a consensus sequence of E2CHIKV and a recombinant protein (E2*CHIKV). Mice were immunized with different homologous and heterologous DNAprime-E2* protein boost strategies, and the specific humoral and cellular immune responses were accessed. We found that mice immunized with heterologous non-targeted DNA prime- E2*CHIKV protein boost developed high levels of neutralizing antibodies, as well as specific IFN-γ producing cells and polyfunctional CD4+ and CD8+ T cells. We also identified 14 potential epitopes along the E2CHIKV protein. Furthermore, immunization with recombinant E2*CHIKV combined with the adjuvant AS03 presented the highest humoral response with neutralizing capacity. Finally, we show that the heterologous prime-boost strategy with the non-targeted pVAX-E2 DNA vaccine as the prime followed by E2* protein + AS03 boost is a promising combination to elicit a broad humoral and cellular immune response. Together, our data highlights the importance of E2CHIKV for the development of a CHIKV vaccine.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity

Coirada

Fernandes

Mello

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…E2 CHIKV recombinant protein formulated with an adjuvant Poly (I:C) induced efficient E2 CHIKV -specific humoral and cellular immune responses [190]. However, the excellent safety profiles of inactivated and protein subunit vaccines come at the expense of their efficacy, since both vaccine platforms require good and immunogenic adjuvants [189][190][191]. LAV is highly immunogenic compared to the other platforms since the attenuated strain retains a weakened replicating capacity and thus, can induce stronger immune responses.…”

Section: The Current Development Of Vaccine Candidates Against Chikvmentioning

confidence: 99%

“…Upon challenge, vaccinated mice had undetectable levels of viral load in blood and tissues [ 189 ]. E2 CHIKV recombinant protein formulated with an adjuvant Poly (I:C) induced efficient E2 CHIKV -specific humoral and cellular immune responses [ 190 ]. However, the excellent safety profiles of inactivated and protein subunit vaccines come at the expense of their efficacy, since both vaccine platforms require good and immunogenic adjuvants [ 189 , 190 , 191 ].…”

Section: The Current Development Of Vaccine Candidates Against Chikvmentioning

confidence: 99%

Understanding the Biology and Immune Pathogenesis of Chikungunya Virus Infection for Diagnostic and Vaccine Development

Hakim¹,

Aman²

2022

Viruses

View full text Add to dashboard Cite

Chikungunya virus, the causative agent of chikungunya fever, is generally characterized by the sudden onset of symptoms, including fever, rash, myalgia, and headache. In some patients, acute chikungunya virus infection progresses to severe and chronic arthralgia that persists for years. Chikungunya infection is more commonly identified in tropical and subtropical regions. However, recent expansions and epidemics in the temperate regions have raised concerns about the future public health impact of chikungunya diseases. Several underlying factors have likely contributed to the recent re-emergence of chikungunya infection, including urbanization, human travel, viral adaptation to mosquito vectors, lack of effective control measures, and the spread of mosquito vectors to new regions. However, the true burden of chikungunya disease is most likely to be underestimated, particularly in developing countries, due to the lack of standard diagnostic assays and clinical manifestations overlapping with those of other endemic viral infections in the regions. Additionally, there have been no chikungunya vaccines available to prevent the infection. Thus, it is important to update our understanding of the immunopathogenesis of chikungunya infection, its clinical manifestations, the diagnosis, and the development of chikungunya vaccines.

show abstract

An overview of anti-Chikungunya antibody response in natural infection and vaccine-mediated immunity, including anti-CHIKV vaccine candidates and monoclonal antibodies targeting diverse epitopes on the viral envelope

Chandley,

Lukose,

Kumar

et al. 2023

The Microbe

View full text Add to dashboard Cite

Prime-boost with Chikungunya virus E2 envelope protein combined with Poly (I:C) induces specific humoral and cellular immune responses

Cited by 7 publications

References 33 publications

Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity

Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity

Understanding the Biology and Immune Pathogenesis of Chikungunya Virus Infection for Diagnostic and Vaccine Development

An overview of anti-Chikungunya antibody response in natural infection and vaccine-mediated immunity, including anti-CHIKV vaccine candidates and monoclonal antibodies targeting diverse epitopes on the viral envelope

Contact Info

Product

Resources

About